Acrigen Biosciences

Acrigen Biosciences, an early-stage biotechnology company based in Berkeley, California, is focused on developing life-saving genetic therapies utilizing its proprietary precision gene editing technology. Co-founded in 2019 by Dr. Joseph Bondy-Denomy, an Associate Professor at UCSF and discoverer of anti-CRISPR proteins, and Dr. David Rabuka, former Founder and CSO of Redwood Biosciences, the company aims to treat genetic disorders through a pipeline of therapies. Its technology leverages novel CRISPR-Cas gene editors coupled with anti-CRISPR proteins to enhance the precision, efficacy, and safety of genetic therapies. Acrigen Biosciences recently secured a $1.00M grant investment from the National Science Foundation on February 24, 2022. With a mission to bring precision genetic therapies to the clinic, the company operates in the biotechnology industry, showcasing its potential for significant impact in the field.